Adaptimmune Therapeutics (ADAP)
(Real Time Quote from BATS)
$1.12 USD
+0.03 (2.75%)
Updated Sep 9, 2024 03:43 PM ET
NA Value
NA Growth NA Momentum NA VGMAdaptimmune Therapeutics PLC (ADAP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$2.83 | $4.00 | $1.00 | 159.63% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Adaptimmune Therapeutics PLC comes to $2.83. The forecasts range from a low of $1.00 to a high of $4.00. The average price target represents an increase of 159.63% from the last closing price of $1.09.
Analyst Price Targets (8 )
Broker Rating
Adaptimmune Therapeutics PLC currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy, representing 62.5% of all recommendations. A month ago, Strong Buy represented 62.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.00 | 2.00 | 2.00 | 2.14 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
8/12/2024 | Wells Fargo Securities | Yanan Zhu | Hold | Hold |
8/12/2024 | SVB Securities | Jonathan W Chang | Hold | Hold |
7/30/2024 | H.C. Wainwright & Co. | Arthur He | Not Available | Strong Buy |
5/30/2024 | Scotiabank | George Farmer | Not Available | Strong Buy |
5/17/2024 | Mizuho SecuritiesUSA | Graig Suvannavejh | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
12/1/2023 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 8 |
Average Target Price | $2.83 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 86 of 253 |
Current Quarter EPS Est: | -0.17 |
ADAP FAQs
Adaptimmune Therapeutics PLC (ADAP) currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Adaptimmune Therapeutics PLC (ADAP) is $2.83. The current on short-term price targets is based on 4 reports.
The forecasts for Adaptimmune Therapeutics PLC (ADAP) range from a low of $1 to a high of $4. The average price target represents a increase of $159.63 from the last closing price of $1.09.
The current UPSIDE for Adaptimmune Therapeutics PLC (ADAP) is 159.63%
Based on short-term price targets offered by eight analysts, the average price target for Adaptimmune Therapeutics PLC comes to $2.83. The forecasts range from a low of $1.00 to a high of $4.00. The average price target represents an increase of 159.63% from the last closing price of $1.09.